Developer of biosimilar theraputics
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars.

P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace.

H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. 

The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. 

H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders.

Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. 

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.

H.R. 6201 - Families First Coronavirus Response Act  -Implementation -  Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 748 - The CARES Act - Implementation-  Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation -  Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. 

H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.

S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. 

Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE
NATHANSON+HAUCK
601 13th Street NW, Suite 290 North, Washington, DC, 20005, US
MELANIE JAN NATHANSON MEGAN HAUCK MARSHALL